ANI Pharmaceuticals (NASDAQ:ANIP) Research Coverage Started at Leerink Partners

Leerink Partners assumed coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report report published on Wednesday morning, Marketbeat.com reports. The firm issued an outperform rating and a $80.00 price objective on the specialty pharmaceutical company’s stock.

A number of other equities analysts also recently commented on ANIP. Raymond James boosted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Piper Sandler began coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price for the company. Finally, StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $56.59 on Wednesday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock’s fifty day moving average price is $58.01 and its 200-day moving average price is $60.33. The firm has a market cap of $1.19 billion, a P/E ratio of -102.89 and a beta of 0.73. ANI Pharmaceuticals has a 12 month low of $51.79 and a 12 month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same quarter last year, the firm posted $1.05 EPS. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities research analysts expect that ANI Pharmaceuticals will post 3.87 earnings per share for the current fiscal year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the sale, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,731 shares of company stock worth $2,015,861. 12.70% of the stock is owned by insiders.

Institutional Trading of ANI Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its stake in shares of ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock worth $705,000 after purchasing an additional 691 shares during the last quarter. Hohimer Wealth Management LLC acquired a new position in ANI Pharmaceuticals in the 3rd quarter worth approximately $264,000. Geode Capital Management LLC raised its position in ANI Pharmaceuticals by 4.2% during the 3rd quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after buying an additional 17,314 shares during the last quarter. Barclays PLC lifted its stake in ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after acquiring an additional 135,003 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at $405,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.